IP Library › Assignment 067694/0242
Patent Assignment
Reel/Frame 067694/0242

Assignment of Assignor's Interest

Recorded: 2024-06-11 Pages: 12
Assignor
GENZYME CORPORATION
Executed: 2024-06-07
Assignee
PRINCIPIA BIOPHARMA INC.
55 CORPORATE DRIVE, BRIDGEWATER, NEW JERSEY, 08807
Covered Properties (36)
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
Application: 18/613,641 →
Publication: US 2024/0366585
4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof
Application: 18/268,577 →
Publication: US 2024/0051955
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis
Application: 18/377,540 →
Publication: US 2024/0173313
Crystalline Form of Tolebrutinib
Application: 17/818,846 →
Publication: US 2022/0389011
Crystal Form of Tolebrutinib, Preparation Method Therefor and Use Thereof
Application: 18/568,484 →
Publication: US 2025/0034130
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)
Application: 62/963,238 →
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)
Application: 62/970,502 →
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (Rms)
Application: 63/013,895 →
4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof
Application: 63/130,010 →
4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2H-Imidazo[4,5-C]Pyridin-2-One Derivatives and Salts Thereof
Application: 63/245,288 →
Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof
Application: 63/292,124 →
Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof
Application: 63/432,169 →
Methods of Making Tolebrutinib
Application: 63/351,996 →
Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)
Application: 63/341,486 →
Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)
Application: 63/433,853 →
Methods of Making Modified Btk Inhibitors
Application: 63/354,330 →
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis
Application: 63/357,465 →
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis
Application: 63/433,866 →
Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One
Application: 63/433,824 →
Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One
Application: 18/545,029 →
Publication: US 2024/0238267
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis
Application: 63/415,027 →
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis
Application: 63/433,873 →
Methods of Diagnosing and Treating Multiple Sclerosis
Application: 63/482,714 →
Methods of Diagnosing and Treating Multiple Sclerosis
Application: 63/623,681 →
Methods of Making Tolebrutinib
Application: 63/561,794 →
Methods of Making Tolebrutinib
Application: 63/564,100 →
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
Application: 17/151,954 →
Publication: US 2021/0244720
4-Amino-3-(4-Phenoxyphenyl)-1,3-Dihydro-2HIMIDAZO[4,5-C]Pyridin-2-One Derivatives and Salts Thereof
Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and Derivatives Thereof
Methods of Making Tolebrutinib
Therapeutic Tyrosine Kinase Inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Disease (Mogad)
Methods of Making Modified Btk Inhibitors
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis and Myasthenia Gravis
Drug Formulations of (R)-1-(1-Acryloylpiperidin-3-Yl)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis
Methods of Diagnosing and Treating Multiple Sclerosis
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 11, 2021
From: CHO, MEEHYUNG; TURNER, TIMOTHY J.; WALLSTROEM, ERIK
To: GENZYME CORPORATION
Reel/Frame 056201/0542 →
Assignment of Assignor's Interest Jun 22, 2021
From: CHO, MEEHYUNG; TURNER, TIMOTHY J.; WALLSTROEM, ERIK
To: GENZYME CORPORATION
Reel/Frame 056619/0763 →
Assignment of Assignor's Interest Dec 21, 2021
From: ARABEYRE-FABRE, CATHERINE; MOLINER, PATRICIA; BOISNARD, SABINE; SALLABERRY, DAMIEN
To: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Reel/Frame 058447/0557 →
Assignment of Assignor's Interest Dec 21, 2021
From: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
To: GENZYME CORPORATION
Reel/Frame 058447/0585 →
Assignment of Assignor's Interest Aug 10, 2022
From: CHEN, MINHUA; SHI, JIAMING
To: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
Reel/Frame 060770/0972 →
Assignment of Assignor's Interest Feb 3, 2023
From: OCHSENBEIN, PHILIPPE
To: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Reel/Frame 062588/0951 →
Assignment of Assignor's Interest Feb 3, 2023
From: PRINCIPIA BIOPHARMA INC.
To: GENZYME CORPORATION
Reel/Frame 062589/0028 →
Assignment of Assignor's Interest Feb 3, 2023
From: OWENS, TIM
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 062588/0894 →
Assignment of Assignor's Interest Feb 3, 2023
From: DIAZ, KRISTA
To: CURIA GLOBAL, INC.
Reel/Frame 062588/0985 →
Assignment of Assignor's Interest Feb 3, 2023
From: CURIA GLOBAL, INC.
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 062660/0767 →
Assignment of Assignor's Interest Feb 3, 2023
From: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
To: GENZYME CORPORATION
Reel/Frame 062589/0091 →
Assignment of Assignor's Interest Jun 14, 2023
From: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
To: GENZYME CORPORATION
Reel/Frame 063945/0802 →
Assignment of Assignor's Interest Jun 29, 2023
From: SYED, SANA
To: GENZYME CORPORATION
Reel/Frame 064109/0956 →
Assignment of Assignor's Interest Jun 29, 2023
From: TURNER, TIMOTHY J.; WALLSTROEM, ERIK
To: GENZYME CORPORATION
Reel/Frame 064117/0001 →
Assignment of Assignor's Interest Jul 5, 2023
From: PRINCIPIA BIOPHARMA INC.
To: GENZYME CORPORATION
Reel/Frame 064154/0551 →
Assignment of Assignor's Interest Jul 5, 2023
From: KANE, JOHN L., JR.; TURNER, TIMOTHY J.
To: GENZYME CORPORATION
Reel/Frame 064154/0442 →
Assignment of Assignor's Interest Jul 5, 2023
From: OWENS, TIMOTHY D.
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 064154/0540 →
Assignment of Assignor's Interest Jul 5, 2023
From: BAILLY, FRÉDÉRIC; BORIE, CYRIL; BOSCH, MICHAËL; CABOS, CLAUDE
To: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Reel/Frame 064152/0341 →
Assignment of Assignor's Interest Jul 5, 2023
From: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
To: GENZYME CORPORATION
Reel/Frame 064152/0360 →
Assignment of Assignor's Interest Jul 5, 2023
From: BENELLI, CHRISTOPHE; JANSSENS, LAURENCE; CHARAUDEAU, ALEXIS; RODIER, FABIEN
To: SANOFI CHIMIE
Reel/Frame 064152/0367 →
Assignment of Assignor's Interest Jul 5, 2023
From: SANOFI CHIMIE
To: GENZYME CORPORATION
Reel/Frame 064152/0402 →
Assignment of Assignor's Interest Jul 18, 2023
From: REICH, DANIEL S.; JACOBSEN, STEVEN
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 064296/0731 →
Assignment of Assignor's Interest Jul 18, 2023
From: BLAZIER, ANNA; OFENGEIM, DIMITRY; WIRAK, GREGORY
To: GENZYME CORPORATION
Reel/Frame 064296/0935 →
Assignment of Assignor's Interest Aug 23, 2023
From: CALDERONE, MARILYN; VIAULT, CAROLINE
To: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
Reel/Frame 064674/0586 →
Assignment of Assignor's Interest Aug 23, 2023
From: SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT
To: GENZYME CORPORATION
Reel/Frame 064674/0605 →